Sex differences in adenosine deaminase activity of stroke patients

Background: Adenosine deaminase (ADA) catalyzes the irreversible hydrolytic deamination of adenosine to inosine. The purpose of this study was to determine the plasma activities of total adenosine deaminase (ADAT), and its isoenzymes, ADA1 and ADA2, and ADA1/ADA2 ratio of male and female ischemic st...

Full description

Saved in:
Bibliographic Details
Published inClinical chemistry and laboratory medicine Vol. 46; no. 4; pp. 506 - 509
Main Authors Tavilani, Heidar, Sheikh, Nasrin, Vaisi-raygani, Asad, Setarehbadi, Rohollah
Format Journal Article
LanguageEnglish
Published Berlin Walter de Gruyter 01.01.2008
New York, NY
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Background: Adenosine deaminase (ADA) catalyzes the irreversible hydrolytic deamination of adenosine to inosine. The purpose of this study was to determine the plasma activities of total adenosine deaminase (ADAT), and its isoenzymes, ADA1 and ADA2, and ADA1/ADA2 ratio of male and female ischemic stroke patients. Methods: We determined activities of plasma ADAT, ADA1, ADA2 and ADA1/ADA2 ratio in 30 patients (15 men and 15 women) with acute ischemic stroke within 12 h of the onset of the attack, as well as in 30 control subjects (15 men and 15 women) of comparable age. Results: There were significant differences between the ADA1 activity and ADA1/ADA2 ratio in male and female stroke patients (p<0.05). Compared with male stroke subjects, females had higher ADA1 activity and ADA1/ADA2 ratios. There were no significant differences between activities of ADAT and ADA2 in men and women of the stroke and control groups. In addition, the Canadian Neurological Scale in men was significantly higher than that of women in the stroke group (p<0.05). Conclusions: Our results suggest that the primary mechanism in men with ischemic stroke might involve the reduction of ADA1 activity. The reduction is probably an adaptation mechanism for induced increase in adenosine availability and protection of brain to ischemic injury. Clin Chem Lab Med 2008;46:506–9.
Bibliography:ark:/67375/QT4-ZDFZ3606-D
ArticleID:cclm.2008.108
cclm.2008.108.pdf
istex:61928800DD0D7CCE631922BC8A3BEAD870ED6178
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1434-6621
1437-4331
DOI:10.1515/CCLM.2008.108